World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
53836
World Ranking
8752
National Ranking
4512

Overview

Eric K. Rowinsky is affiliated with Eli Lilly in the United States and has contributed extensively to research in medicine, with a focus on oncology and related subfields. Their work spans various aspects of cancer research, immunology, biotechnology, and genetics, with a significant emphasis on CAR-T cell therapy and virus-based gene therapies.

Rowinsky's research portfolio includes 31 publications in medicine and 17 in biochemistry, genetics, and molecular biology. Among the primary subfields addressed are oncology, immunology, biotechnology, genetics, and radiology, nuclear medicine, and imaging. The scientist's main topics of investigation cover:

  • CAR-T cell therapy research
  • Cancer Research and Treatments
  • Virus-based gene therapy research
  • Biosimilars and Bioanalytical Methods
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer Immunotherapy and Biomarkers
  • Immune cells in cancer

Rowinsky has published in several scientific venues, with the most frequent being the Journal of Clinical Oncology (9 papers), followed by Cancer Research (5), Regular and Young Investigator Award Abstracts (2), Investigational New Drugs (1), and The Lancet Oncology (1).

Notable recent papers include:

  • "Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma," 2020, Investigational New Drugs
  • "LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study," 2024, The Lancet Oncology
  • "Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer," 2024, JAMA Oncology
  • "A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer," 2022, Journal of Clinical Oncology
  • "A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report," 2020, Journal of Clinical Oncology

The scientist collaborates frequently with researchers such as Marwan Fakih, Jessica Wenthe, Emma Eriksson, Gustav Ullenhag, and Dongqi Chen, each representing recurrent contributions to related research themes and clinical studies.

Best Publications

  • Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

    James A. Bonner;Paul M. Harari;Jordi Giralt;Nozar Azarnia

  • Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

    James A Bonner;Paul M Harari;Jordi Giralt;Roger B Cohen

  • Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.

    William P. McGuire;Eric K. Rowinsky;Neil B. Rosenshein;Francis C. Grumbine

  • Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

    Román Pérez-Soler;Abraham Chachoua;Lisa A. Hammond;Eric K. Rowinsky

  • Taxol: A Novel Investigational Antimicrotubule Agent

    Eric K. Rowinsky;Lorranie A. Cazenave;Ross C. Donehower

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

    Manuel Hidalgo;Lillian L. Siu;John Nemunaitis;Jinee Rizzo

  • ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

    Malcolm R Ranson;Lisa A Hammond;David R Ferry;Mark Kris

  • Clinical toxicities encountered with paclitaxel (Taxol)

    Rowinsky Ek;Eisenhauer Ea;Chaudhry;Arbuck Sg

  • Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)

    George W. Sledge;Donna Neuberg;Patricia Bernardo;James N. Ingle

  • Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial

    Philip Bonomi;KyungMann Kim;Diane Fairclough;David Cella

  • The Current Status of Camptothecin Analogues as Antitumor Agents

    William J. Slichenmyer;Eric K. Rowinsky;Ross C. Donehower;Scott H. Kaufmann

  • The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

    Manuel Hidalgo;Eric K Rowinsky

  • Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

    Jennifer L. Spratlin;Roger B. Cohen;Matthew Eadens;Lia Gore

  • Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development

    Eric K. Rowinsky;Jolene J. Windle;Daniel D. Von Hoff

  • Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

    Heinz Josef Lenz;Eric Van Cutsem;Shirin Khambata-Ford;Robert J. Mayer

  • Sequences of Taxol and Cisplatin: A Phase I and Pharmacologic Study

    E K Rowinsky;M R Gilbert;W P McGuire;D A Noe

  • Taxol: the first of the taxanes, an important new class of antitumor agents.

    Eric K. Rowinsky;Eric K. Rowinsky;Nicole Onetto;Nicole Onetto;Renzo M. Canetta;Renzo M. Canetta;Susan G. Arbuck;Susan G. Arbuck

  • Cardiac disturbances during the administration of taxol.

    Eric K. Rowinsky;William P. McGuire;Thomas Guarnieri;Jason S. Fisherman

  • The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics.

    Eric K. Rowinsky;Ross C. Donehower

Frequent Co-Authors

Ross C. Donehower
Ross C. Donehower Johns Hopkins University
David S. Ettinger
David S. Ettinger Johns Hopkins University
Sharyn D. Baker
Sharyn D. Baker The Ohio State University
Arlene A. Forastiere
Arlene A. Forastiere Johns Hopkins University
Manuel Hidalgo
Manuel Hidalgo Cornell University
Amita Patnaik
Amita Patnaik University of Chicago
Richard J. Jones
Richard J. Jones Johns Hopkins University
Alex A. Adjei
Alex A. Adjei Cleveland Clinic
Yung-Chi Cheng
Yung-Chi Cheng Yale University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t always require pursuing a traditional MD. There are many alternative pathways and online degrees in healthcare offering flexibility, diverse roles, and quicker entry into the workforce.

Many students begin their medical careers through direct entry nursing programs that allow individuals with a bachelor’s degree (in any field) to transition into nursing quickly. For those interested in nursing but looking for less strenuous entry requirements, an lpn program without teas test can be a good option, bypassing standardized entrance exams.

Non-clinical healthcare roles are always in demand. Earning a degree from one of the best online medical billing and coding schools that accept fafsa allows students to work in the administrative backbone of healthcare, often fully online and with financial aid options. Similarly, moving into leadership roles is possible with healthcare administration degree programs available online, designed for both new entrants and working professionals seeking advancement.

These pathways provide practical alternatives for those seeking fulfilling healthcare careers without the lengthy commitment of medical school.

Best Scientists Citing Eric K. Rowinsky

Trending Scientists

Recently Published Articles